Drugs / CGF166
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02132130 | Jun 2014 → Dec 2019 | hearing loss disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CGF166 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02132130 ↗ |
| Route | Other | “for administration via intra-labyrinthine infusion” NCT02132130 ↗ |